Loading...
India's amiodarone imports from GERMANY total $187 across 3 shipments from 2 foreign suppliers. MERCKLE GMBH leads with $109 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for amiodarone — a concentrated sourcing relationship with select suppliers from GERMANY.
MERCKLE GMBH is the leading Amiodarone supplier from GERMANY to India, with import value of $109 across 2 shipments. The top 5 suppliers — MERCKLE GMBH, Merckle Gmbh — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | MERCKLE GMBH | $109 | 2 | 57.9% |
| 2 | Merckle Gmbh | $79 | 1 | 42.1% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED | $109 | 2 | 57.9% |
| 2 | TEVAPHARM INDIA PRIVATE LIMITED | $79 | 1 | 42.1% |
Visual overview of India's amiodarone GERMANY to India import corridor — top suppliers, destinations, pricing, and trade routes
GERMANY → India trade corridor intelligence
As of April 2026, the Germany to India pharmaceutical import corridor remains active, with no significant disruptions reported. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently, with standard congestion levels. Freight rates have stabilized, and the exchange rate between the Euro and the Indian Rupee remains favorable for trade. No significant shipping disruptions have been reported, ensuring a steady flow of pharmaceutical imports from Germany to India.
India's Production Linked Incentive (PLI) scheme aims to boost domestic manufacturing and reduce import dependency. While the scheme primarily targets the production of bulk drugs and active pharmaceutical ingredients, it may indirectly affect the import of finished formulations by encouraging domestic production of certain products. However, specialized formulations like Amiodarone may continue to be imported due to the lack of domestic manufacturing capabilities. Import substitution policies are being evaluated, but their impact on finished formulation imports from Germany is expected to be minimal in the short term.
The trade relationship between India and Germany is strong, with both countries engaging in regular dialogues to enhance bilateral trade, including pharmaceuticals. Discussions have focused on mutual recognition of Good Manufacturing Practices (GMP), facilitating smoother regulatory approvals for pharmaceutical imports. Ongoing negotiations aim to streamline customs procedures and address any trade barriers, further strengthening the pharmaceutical trade corridor between Germany and India.
The landed cost of importing Amiodarone formulations from Germany to India includes the following components:
A detailed per-unit estimate requires specific CIF values and shipping details.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Amiodarone into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the manufacturing site and the product be registered prior to import. An Import Registration Certificate is necessary for each product intended for import. The application process involves submitting Form 40 or 41 to the CDSCO, along with the requisite fee and supporting documents, including a Certificate of Pharmaceutical Product (CoPP) and a Free Sale Certificate from the country of origin. The timeline for obtaining registration can vary, but it typically ranges from 6 to 12 months, depending on the completeness of the application and the regulatory review process. For Amiodarone formulations under HS Code 30049099, specific requirements include stability data demonstrating compliance with ICH guidelines, a CoA, and evidence of Good Manufacturing Practice (GMP) compliance. Additionally, a No Objection Certificate (NOC) from the manufacturer may be required to confirm that the product is not patented or under exclusive marketing rights in India.
Imported Amiodarone formulations must undergo quality testing at CDSCO-approved laboratories to ensure compliance with Indian standards. Each batch requires a Certificate of Analysis (CoA) confirming that the product meets the specifications outlined in the Indian Pharmacopoeia. Stability data, adhering to ICH Zone IV guidelines, must be provided to demonstrate the product's stability under India's climatic conditions. Upon arrival, customs drug inspectors conduct port inspections, which may include sampling for quality testing. The batch-wise testing process can take several weeks, potentially leading to delays in market availability. If a batch fails to meet the required standards, it may be rejected, leading to the need for re-exportation or destruction, depending on the circumstances.
Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. However, the PLI scheme primarily targets domestic production and does not directly alter import policies for finished formulations. Bilateral agreements between India and Germany have facilitated smoother trade relations, including mutual recognition of GMP standards, which may expedite the import process for German manufacturers. These agreements aim to streamline regulatory procedures and enhance the efficiency of pharmaceutical imports.
Market demand, customs duty structure, and competitive landscape · Import duty: 17.10%
India imports finished Amiodarone formulations to meet the therapeutic needs of patients requiring antiarrhythmic treatment. The demand for imported formulations is driven by the availability of patented or branded products, specific dosage forms not produced domestically, and the need for high-quality standards. While India has a robust pharmaceutical manufacturing sector, certain specialized formulations and dosage forms of Amiodarone are not produced locally, necessitating imports. The market size for Amiodarone formulations in India is substantial, with imports contributing significantly to the overall supply.
The import duty structure for Amiodarone formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, and a Secondary Higher Education Cess of 1%, totaling 13%. Additionally, a Countervailing Duty (CVD) of 6% is applicable, bringing the total duty to 19%. The Social Welfare Surcharge (SWS) is 10% of the BCD, amounting to 1%. The Integrated Goods and Services Tax (IGST) is 12%, calculated on the sum of the CIF value plus the total duty. There are no exemptions or concessional rates applicable for imports from Germany under the Most Favored Nation (MFN) status.
India sources Amiodarone formulations from Germany due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms not produced domestically. German manufacturers offer high-quality products that meet stringent regulatory requirements, providing a competitive advantage in the Indian market. While other countries like China and the United States also export Amiodarone formulations to India, Germany's reputation for quality and reliability positions it favorably in the Indian pharmaceutical import market.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Amiodarone formulations from Germany due to the country's advanced pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms not produced domestically. German manufacturers offer high-quality products that meet stringent regulatory requirements, providing a competitive advantage in the Indian market. The importation of these formulations ensures that patients in India have access to effective and reliable antiarrhythmic treatments.
When compared to other sources like China and the United States, Germany offers a competitive advantage in terms of product quality, regulatory compliance, and reliability. German pharmaceutical products are known for their high standards and consistency, which are critical in the healthcare sector. While China may offer lower prices, concerns about quality and regulatory compliance can be a deterrent. The United States provides high-quality products but may have higher costs and longer shipping times. Germany's unique advantage lies in its balance of quality, cost, and reliability, making it a preferred source for Amiodarone formulations in India.
Indian importers face several supply chain risks when sourcing Amiodarone formulations from Germany, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Amiodarone suppliers from GERMANY to India include MERCKLE GMBH, Merckle Gmbh. The leading supplier is MERCKLE GMBH with import value of $109 USD across 2 shipments. India imported Amiodarone worth $187 USD from GERMANY in total across 3 shipments.
India imported Amiodarone worth $187 USD from GERMANY across 3 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Amiodarone sourced from GERMANY include ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED, TEVAPHARM INDIA PRIVATE LIMITED. The largest buyer is ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED with $109 in imports across 2 shipments.
The total value of Amiodarone imports from GERMANY to India is $187 USD, across 3 shipments and 2 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3 Verified Shipments
2 suppliers, 2 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists